For 60 years, sequence and structure has been the primary lens to understand protein function. It’s now time to look beyond and leverage the orchestration of protein function within cells.
Cedilla Therapeutics is bringing a new dimension to precision oncology. We have discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. Our conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2.
We are a driven and patient-focused team.
Cedilla Therapeutics is bringing a new dimension to precision oncology. We have discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. Our conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2.
We are a driven and patient-focused team.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $138.8M
Founded date: 2018
Investors 1
| Date | Name | Website |
| 29.10.2021 | RA Capital... | racap.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.10.2021 | Series B | $82.6M | RA Capital... |
| 24.04.2018 | Series A | $56.2M | Third Rock... |
Mentions in press and media 11
| Date | Title | Description |
| 26.10.2021 | Daily funding roundup - October 25, 2021 | Workit Health raised $90M; Cedilla Therapeutics secured $25; Selfbook landed $25M Thrasio: Thrasio is a Boston-based outfit that acquires and aggregates third-party merchants selling on Amazon and other marketplace platforms. Thrasio has ra... |
| 25.10.2021 | Cedilla Therapeutics raised $25M; Closes $82.6M Series B | Cedilla Therapeutics, a Cambridge, Mass.-based biotechnology company focused on precision oncology, raised $25m in an expansion of its Series B financing, bringing the total amount raised to $82.6m. The Series B expansion includes new inves... |
| 25.10.2021 | Cedilla Therapeutics : Completes $82.6M Series B Financing | Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced that it has raised an additional $25 million in an expansion of its Series B financing, bringing the total amount raised to $82.6 ... |
| 25.10.2021 | Cedilla Therapeutics Inks $82.6M Series B | CAMBRIDGE, MA, Cedilla Therapeutics has raised $82.6 million in Series B. >> Click here for more funding data on Cedilla Therapeutics >> To export Cedilla Therapeutics funding data to PDF and Excel, click here Cedilla The... |
| 13.10.2020 | Cedilla Therapeutics Closes $57.6 Million Series B | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cedilla Therapeutics, a private biotechnology company developing targeted small molecules for the treatment of cancer and other diseases caused by protein dysregulation, today announced the closing of a $5... |
| 13.10.2020 | Boxer Capital Co-leads $57.6M Series B for Cedilla Therapeutics | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cedilla Therapeutics, a private biotechnology company developing targeted small molecules for the treatment of cancer and other diseases caused by protein dysregulation, today announced the closing of a $5... |
| 13.10.2020 | Casdin Capital Co-leads $57.6M Series B for Cedilla Therapeutics | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cedilla Therapeutics, a private biotechnology company developing targeted small molecules for the treatment of cancer and other diseases caused by protein dysregulation, today announced the closing of a $5... |
| 08.10.2020 | The CRISPR Nobel was about more than two women scientists. It was about all of them | News that Jennifer Doudna and Emmanuelle Charpentier were awarded this year’s Nobel Prize in chemistry “for the development of a method for genome editing” known as CRISPR-Cas9 was exciting for several reasons. One is the impact of the disc... |
| 24.04.2018 | Third Rock Invests $56.2M in Series A Funding for Cedilla Therapeutics | Cedilla Therapeutics, a new biotechnology company broadening the reach of small molecule therapeutics by discovering and exploiting unique insights into protein stability, launched today with $56.2 million in Series A funding from Third Roc... |
| 24.04.2018 | Third Rock Invests $56.2M in Series A Funding for Cedilla Therapeutics | Cedilla Therapeutics, a new biotechnology company broadening the reach of small molecule therapeutics by discovering and exploiting unique insights into protein stability, launched today with $56.2 million in Series A funding from Third Roc... |
Show more